Progress of Immunotherapy Combined with Anti-Angiogenesis Therapy in Lung Cancer  

作　　者：Chenyang Zuo Jinyuan Xie Meng Wang Jun Cai Qingqing Ye Chenyang Zuo;Jinyuan Xie;Meng Wang;Jun Cai;Qingqing Ye(Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, China;Department of Joint Surgery and Sports Medicine, Jingmen Central Hospital, Jingmen, China;Department of Breast Surgery, First Affiliated Hospital of Yangtze University, Jingzhou, China)

机构地区：[1]Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, China [2]Department of Joint Surgery and Sports Medicine, Jingmen Central Hospital, Jingmen, China [3]Department of Breast Surgery, First Affiliated Hospital of Yangtze University, Jingzhou, China

出　　处：《Journal of Biosciences and Medicines》2024年第9期183-195,共13页生物科学与医学（英文）

摘　　要：Lung cancer is the most prevalent and fatal cancer in China and even around the world, and many patients are found in the late stage of lung cancer. For the treatment of advanced lung cancer, in addition to traditional chemotherapy modalities, many emerging treatments are increasingly significant, such as immunotherapy, anti-angiogenic therapy, and targeted therapy. An increasing number of studies have now shown that anti-angiogenic therapy improves the immune microenvironment by enhancing tumor immunity through normalization of tumor vessels. Immunization combined with anti-angiogenic therapy can exert synergistic effects and improve the prognosis of patients. This article summarizes the extent of benefit, current clinical study data, and future prospects of immunotherapy combined with anti-angiogenic agents in the treatment of advanced NSCLC.Lung cancer is the most prevalent and fatal cancer in China and even around the world, and many patients are found in the late stage of lung cancer. For the treatment of advanced lung cancer, in addition to traditional chemotherapy modalities, many emerging treatments are increasingly significant, such as immunotherapy, anti-angiogenic therapy, and targeted therapy. An increasing number of studies have now shown that anti-angiogenic therapy improves the immune microenvironment by enhancing tumor immunity through normalization of tumor vessels. Immunization combined with anti-angiogenic therapy can exert synergistic effects and improve the prognosis of patients. This article summarizes the extent of benefit, current clinical study data, and future prospects of immunotherapy combined with anti-angiogenic agents in the treatment of advanced NSCLC.

关 键 词：IMMUNOTHERAPY Anti-Angiogenic Therapy Lung Cancer Tumor Immune Microenvironment 

分 类 号：R73[医药卫生—肿瘤]